A Patient-Friendly Guide to Verteporfin (Visudyne) Treatment for Retinal Disease

Photodynamic therapy (PDT) is a specialized treatment sometimes used by retina specialists to treat certain diseases affecting the retina and choroid, the blood vessel layer beneath the retina. In retina care, PDT most commonly uses a medication called verteporfin (brand name Visudyne). This treatment may be recommended for conditions such as central serous chorioretinopathy (CSC or CSCR), polypoidal choroidal vasculopathy (PCV), and selected cases of choroidal neovascularization (CNV), including some forms of wet age-related macular degeneration.

The retina is the thin layer of nerve tissue lining the back of the eye that captures light and sends visual signals to the brain so we can see. Beneath the retina lies the choroid, a layer rich in blood vessels that nourishes the retina. In some retinal diseases, abnormal blood vessel leakage or excessive choroidal activity can cause fluid to build up under the retina, leading to blurry vision, distortion, or blind spots. PDT works by helping reduce abnormal leakage while minimizing damage to healthy surrounding tissue.

During retinal PDT, a light-sensitive medication called verteporfin is given through an intravenous (IV) line in your arm. The medication travels through the bloodstream and concentrates in abnormal blood vessels or targeted tissue beneath the retina. A low-energy, non-thermal laser is then carefully applied to the eye to activate the medication in the treated area. Once activated, the medication helps close abnormal leaking blood vessels and reduce fluid accumulation.

The procedure is usually performed in an outpatient setting and typically takes less than an hour. Before treatment, your pupils are dilated and numbing drops may be used for comfort. The laser treatment itself is generally painless. Most patients do not feel discomfort, although the IV medication may occasionally cause temporary irritation at the injection site.

One of the most important things patients should understand after PDT is light sensitivity. Because verteporfin remains temporarily activated by light, patients must avoid direct sunlight and bright indoor light for approximately 48 hours after treatment. Protective clothing, hats, sunglasses, and staying indoors when possible are recommended during this time. Exposure to bright light too soon may increase the risk of skin reactions.

Vision may remain blurry for several days after treatment, and improvement often occurs gradually over weeks to months depending on the underlying condition. Some patients require more than one PDT session or combination treatment with anti‑VEGF injections, especially in diseases such as PCV or CNV. Retina specialists often monitor response using OCT imaging and retinal angiography to evaluate whether fluid or abnormal blood vessels have improved.

Although retinal PDT is generally considered safe, possible side effects include temporary blurry vision, mild visual dimming, inflammation, or recurrence of fluid over time. Serious complications are uncommon but may include worsening vision or damage to surrounding retinal tissue. Contact your retina specialist if you experience sudden severe vision loss, worsening pain, or other concerning symptoms after treatment.

PDT can be an effective option for selected retinal diseases and may reduce fluid, improve retinal anatomy, and help stabilize or improve vision when carefully matched to the right condition.